Canagliflozin : something new for type 2 diabetes, but is it safe and efficacious?
Data(s) |
01/02/2014
|
---|---|
Resumo |
Evaluation of Inagaki N, Kondo K, Yoshinari T, et al. Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study. Diabetes Obes Metab 2013. [Epub ahead of print] and Cefalu WT, Leiter LA, Yoon KH, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomized, double-blind, phase 3 non-inferiority trial. Lancet 2013;382:941-50 INTRODUCTION Inhibition of the sodium-glucose cotransporter 2 (SGLT2), to promote the excretion of glucose, is a new paradigm in the treatment of type 2 diabetes. AREAS COVERED Canagliflozin is an SGLT2 inhibitor, which has been the subject of two recent clinical trials, which are evaluated. EXPERT OPINION Studies with canagliflozin, in subjects with type 2 diabetes, have shown that its use is associated with reductions in HbA1c and body weight and small reductions in blood pressure and triglycerides, while increasing high-density lipoprotein cholesterol and low-density lipoprotein cholesterol. As monotherapy in Japanese subjects, or in comparison with glimepiride in CANTATA-SU (CANagliflozin Treatment and Trial Analysis versus SUlphonylurea), canagliflozin causes a low incidence of hypoglycemia, and this is an advantage over glimepiride. However, one of the disadvantages with canagliflozin, which was also highlighted in CANTATA-SU, is that canagliflozin can cause urogenital infections, which are not observed with other antidiabetic drugs. The Federal Drug Administration has recently approved canagliflozin for use in type 2 diabetes, while directing that a clinical outcome safety trial be undertaken. We are concerned that canagliflozin has been approved for use in type 2 diabetes prior to a clinical outcome study of efficacy being undertaken and without the outcome of further safety testing. |
Formato |
application/pdf |
Identificador | |
Publicador |
Informa Plc |
Relação |
http://eprints.qut.edu.au/78687/2/78687.pdf DOI:10.1517/14656566.2014.868885 Doggrell, Sheila & McIntyre, Kerry (2014) Canagliflozin : something new for type 2 diabetes, but is it safe and efficacious? Expert Opinion on Pharmacotherapy, 15(3), pp. 437-441. |
Direitos |
Copyright 2014 Informa UK, Ltd. Reproduction in whole or in part not permitted |
Fonte |
School of Biomedical Sciences; Faculty of Health |
Palavras-Chave | #111500 PHARMACOLOGY AND PHARMACEUTICAL SCIENCES #canagliflozin #type 2 diabetes |
Tipo |
Journal Article |